Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating toxoplasmosis by using isoflavanoid compound glabridin

A technology of glabridin and toxoplasmosis, applied in the field of medicine, to achieve the effect of inhibiting invasion and proliferation

Pending Publication Date: 2021-08-03
LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no studies have shown that glabridin is active against Toxoplasma gondii

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating toxoplasmosis by using isoflavanoid compound glabridin
  • Method for treating toxoplasmosis by using isoflavanoid compound glabridin
  • Method for treating toxoplasmosis by using isoflavanoid compound glabridin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The invention provides a method for treating toxoplasmosis by using the isoflavane compound glabridin, and the specific steps are as follows:

[0032] Step 1: Utilize isoflavane compound glabra to make medicines;

[0033] The isoflavane compound glabridin is extracted from licorice;

[0034] The medicine is composed of the following raw materials in parts by weight: 0.01-0.2 parts of isoflavane compound glabridin, 20-30 parts of disintegrating agent, 20-30 parts of filler, 2-6 parts of glidant, adhesive 2-8 parts, 1-3 parts of surfactant, and 1-3 parts of flavoring agent; the disintegrant is one of dry starch, sodium carboxymethyl starch, low-substituted cellulose, and cross-linked PVP. The filler is one of mannitol, lactose, microcrystalline cellulose; the glidant is one of talcum powder, micropowder silica gel, and the binder is starch slurry, methylcellulose, polydimensional One of ketones; the surfactant is one of sodium lauryl sulfate, stearic acid, and the corre...

Embodiment 2

[0043] The medicine is composed of the following raw materials in parts by weight: 0.2 parts of isoflavane compound glabridin, 30 parts of disintegrant, 30 parts of filler, 6 parts of glidant, 8 parts of binder, and 3 parts of surfactant and 3 parts of flavoring agent; the disintegrating agent is sodium starch glycolate, the filler is mannitol, the glidant micropowder silica gel, the binder is starch slurry, and the surfactant is sodium lauryl sulfate, and the flavoring agent is stevioside.

[0044] The specific steps of the preparation method of the medicine are as follows:

[0045] S1: sieve the raw material isoflavane compound glabridin, disintegrant, filler, glidant, binder, surfactant and flavoring agent separately for later use;

[0046] S2: uniformly mixing the isoflavane compound glabridin, a disintegrant, and a filler in a mixer to prepare a medicinal powder;

[0047] S3: making wet granules in a wet granulator with binder, surfactant, flavoring agent and medicinal ...

Embodiment 3

[0051] Determination of the anti-invasion effect of the medicine containing the isoflavane compound glabridin prepared in Example 2 on Toxoplasma gondii:

[0052] The drug was formulated as experimental samples containing the following concentrations of glabridin: 1 μg / mL, 2 μg / mL, 5 μg / mL, 8 μg / mL, 10 μg / mL.

[0053] Method 1: Determination of the anti-invasion effect of glabridin on Toxoplasma gondii RH by indirect immunofluorescence method:

[0054] Step: 1 × 10 containing each concentration of glabridin 5 RH tachyzoites / mL were inoculated in monolayer Vero cells after being treated for 1 h in the incubator, 0.25% DMSO was used as negative control group, and 10 μg / mL pyrimethamine (PYR) was used as positive control group. After 2 hours of invasion, try to wash away the non-invading tachyzoites with PBS. After fixation, antigen retrieval and blocking, the extracellular T. gondii was labeled with mouse anti-T. gondii monoclonal antibody, and the secondary antibody was goat an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for treating toxoplasmosis by using an isoflavanoid compound glabridin. The method comprises the following specific steps: step 1, preparing a medicine by using the isoflavanoid compound glabridin; and step 2, resisting invasion of toxoplasma gondii by the prepared medicine. The isoflavanoid compound glabridin has remarkable activity on toxoplasma gondii, can remarkably inhibit invasion and proliferation of the toxoplasma gondii and can be used for treating toxoplasmosis, and the anti-proliferation and anti-invasion effects of the glabridin are even superior to those of an existing clinically used medicine pyrimethamine; and the medicine prepared from the isoflavanoid compound glabridin is effective to acute toxoplasmosis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a method for treating toxoplasmosis by using the isoflavane compound glabridin. Background technique [0002] Toxoplasma belongs to the subphylum Apicomplexa, class Sporozoasida, subclass Coccidiasina, order Eucoccidiorida, suborder Eimeriina, family Toxoplasmatidae , Toxoplasma. The genus Toxoplasma has only one species, Toxoplasma gondii, commonly known as Toxoplasma gondii. However, according to different regions, different hosts, different virulence, life history and development time, etc., it can be divided into three different genotypes, type Ⅰ (RH and GT-1 strains), type Ⅱ (ME49 and PRU strain) and type III (CEP and VEG strains). The three genotype strains have significantly different virulence phenotypes, among which the type I strain is a virulent strain with a high lethality rate, mainly for acute infection; while the type II and III strains are much lower in toxici...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K9/20A61P33/02C07D311/92A61K36/484
CPCA61K31/352A61K9/2059A61K9/2054A61K9/2027A61P33/02C07D311/92A61K36/484
Inventor 张继瑜邱燕华王玮玮翟斌涛白玉彬杨枭荣周绪正李冰程富胜魏小娟
Owner LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com